ArticleDiscover oncology2026
A bibliometric analysis of the role of apoptosis in breast cancer immunotherapy from 1994 to 2024.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundApoptosis is a fundamental biological process and a central determinant of therapeutic response in breast cancer (BC). Resistance to immunotherapy is increasingly recognized to be driven, in part, by impaired apoptotic signaling. Despite its importance, no systematic bibliometric evaluation has mapped the global research landscape in this field.
methodsThis study examined 1425 publications related to apoptosis in breast cancer immunotherapy from 1994 to 2024 using the Web of Science Core Collection database. Data visualization and analysis were conducted using VOSviewer (version 1.6.19), CiteSpace (version 6.2.R3), and the biblioshiny R package.
resultsThe analysis included 81 countries, 2060 institutions, and 9354 researchers across 536 journals. China leads with 552 publications and 16,922 citations, with Sichuan University identified as the most influential institution (n = 33). Cancers has the highest number of publications (n = 39), while Cancer Research has the most co-citations (3725). Wei Zhang is the most prolific author with 9 publications and an H-index of 6, while D. Hanahan has the highest number of co-citations (n = 153). The current research hotspots mainly include "cell death networks", "177Lu-based radioligand therapy", "immunotherapeutic strategies", "resistance mechanisms" and "precision medicine". Future research emphasizes "integrating multiple cell death mechanisms-based ferroptosis and immunogenic cell death", "developing advanced nanotechnology-based delivery systems and phototherapy modalities", and "leveraging AI-driven biomarker discovery and precision medicine approaches".
conclusionsThis analysis describes the evolution of apoptosis in BC immunotherapy research patterns and identifies emerging research directions that may inform future precision oncology development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.